On Demand Versus Daily Sildenafil for Patients Undergoing Radical Prostatectomy (URO2010)


Università Vita-Salute San Raffaele

Status and phase

Phase 3


Erectile Dysfunction


Drug: Sildenafil

Study type


Funder types



HSR Urology

Details and patient eligibility


Viagra (Sildenafil citrate) is an orally active selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) which is used for the treatment of erectile dysfunction (ED). Objectives: To test the efficacy of Viagra 100mg on demand vs. Viagra 100mg daily (taken either at bedtime or 1 hour prior to sexual intercourse) in restoring erectile function following radical prostatectomy. To test the safety and tolerability of Viagra 100 mg on demand vs. Viagra 100 mg daily after radical prostatectomy.


200 estimated patients




18 to 65 years old


No Healthy Volunteers

Inclusion criteria

  • Subjects who have given written informed consent to participate in the study.
  • Men aged 18-65 years old.
  • Weight range 50-100 Kg.
  • Subjects must be in a stable relationship with the same partner for at least 6 months and willing to attempt sexual intercourse.
  • Normal pre-operative erectile function (defined as IIEF-EF ≥ 26) without the use of therapy or devices for the improvement of erections.
  • Prostatic Specific Antigen (PSA) lower than 10 ng/ml.
  • Clinical prostate cancer stage T1c or T2.
  • Biopsy Gleason sum < 8.

Able to read, understand and provide signed informed consent.

Intra-operative inclusion criteria:

Bilateral nerve sparing radical prostatectomy (both open and robotic assisted radical prostatectomy are accepted) as defined by the surgeon.

Post-operative inclusion criteria:

Histologically-confirmed, organ-confined prostate cancer disease (defined as, Gleason 6 or 7 and, pathological stage T2 or T3a R0 N0).

Exclusion criteria

Subjects presenting with any of the following will not be included in the trial:

  • Subjects in whom sexual activity is inadvisable in the opinion of the investigator such as significant cardiovascular disease in the last 6 months; including cardiac failure, myocardial infarction, unstable angina, stroke or transient ischemic attack (TIA), symptomatic or clinically significant cardiac arrhythmias including atrial fibrillation.
  • Subjects who have a medical history of major hematological, renal, vascular or hepatic abnormalities, those with psychological or social circumstances that would impair their ability to participate reliably in the study, or those who may increase the risk to themselves or others by participating in the study.
  • Subjects who have a medical history of diabetes.
  • Subjects who developed a postoperative complication, namely reoperation for hemorrhage, a documented urinary fistula or the indwelling of catheter for 3 or more weeks.
  • Subjects treated with neo-adjuvant radiotherapy or hormonotherapy.
  • Subjects who have received or are receiving any PDE5 inhibitors.
  • Subjects with known hypersensitivity to Viagra or any component of the study medication.
  • Subjects with resting sitting hypotension (BP < 90/50 mmHg), hypertension (BP > 170/110 mmHg) or orthostatic hypotension.
  • Subjects with severe hepatic; cirrhosis or ALT (Alanine aminotransferase) 2x upper limit of normal) and renal impairment (creatinine clearance 30mL/min) or known history of hereditary degenerative retinal disorders such as retinitis pigmentosa.
  • Subjects who, for medical reasons and/or in the opinion of the investigator, require starting dose of 25mg of Viagra.
  • Subjects who are currently taking or are likely to be treated with nitrates or nitric oxide donors in any form (oral, sublingual, buccal, transdermal, inhalational or as aerosols) on either regular or intermittent basis.
  • Subjects who are receiving concomitant treatment or who during the study are likely to start the treatment with potent CYP3A4 and CYP2C9 inhibitors (e.g. protease inhibitors ritonavir and saquinavir, ketoconazole, itraconazole, Miconazole, nefazadone, claritromycin, troleandomycin erythromycin and cimetidine).
  • Subjects who are currently using any commercially available treatments or non-commercial herbal preparations for erectile dysfunction, e.g. IC injections, vacuum devices, or testosterone patches. Such treatments/devices must not be used at any time during the study.
  • Subjects who have received any investigational drug within the six weeks prior to screening or who are taking any other investigational drug concomitantly.
  • previous prostate surgery or previous hormonal treatment.
  • Subjects at increased risk of priapism e.g. sickle cell disease, multiple myeloma, or with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease) and myeloproliferative disorders (e.g. myeloid leukemia, polycythemia, thrombocytopenia).
  • Subjects with other forms of sexual dysfunction (e.g. retrograde ejaculation, unejaculation, painful ejaculation, premature ejaculation, hypoactive sexual desire and inhibited or absent orgasm).
  • Subjects who, in the opinion of the investigator, abuse alcohol or drugs.
  • Subjects who, in the opinion of the investigator, are not likely to complete the event logs and follow study instructions.
  • Subjects who, in the opinion of the investigator, are not likely to complete the study for whatever reason.

Trial design

Primary purpose




Interventional model

Parallel Assignment


None (Open label)

200 participants in 2 patient groups

Viagra 100 mg daily
Active Comparator group
Drug: Sildenafil
Viagra 100mg on demand
Active Comparator group
Drug: Sildenafil

Trial contacts and locations



Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location


© Copyright 2024 Veeva Systems